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Lactation is a common feeding strategy of eutherian mammals, but its functions go 
beyond feeding the neonates. Ever since Tissier isolated bifidobacteria from the stool of 
breast-fed infants, human milk has been postulated to contain compounds that selectively 
stimulate the growth of bifidobacteria in intestines. However, until relatively recently, 
there have been no reports to link human milk compound(s) with bifidobacterial 
physiology. Over the past decade, successive studies have demonstrated that infant gut-
associated bifidobacteria are equipped with genetic and enzymatic toolsets dedicated to 
assimilation of host-derived glycans, especially human milk oligosaccharides (HMOs). 
Among gut microbes, the presence of enzymes required for degrading HMOs with type-
1 chains is essentially limited to infant gut-associated bifidobacteria, suggesting HMOs 
serve as selected nutrients for the bacteria. In this paper, I shortly discuss the research on 
bifidobacteria and HMOs from a historical perspective, and summarize the roles of 
bifidobacterial enzymes in the assimilation of HMOs with type-1 chains. Based on this 
overview, I suggest the co-evolution between bifidobacteria and human beings mediated 
by HMOs. (169 words) 
 





The mammalian gastrointestinal tract is inhabited by a vast and diverse community 
of microbes1) and their metabolic activity significantly influences the host’s health. In 
mice, short-chain fatty acids produced by intestinal bacteria have been shown to affect 
the body weight, energy balance, and immune response2), while butyric acid produced by 
clostridia is known to induce the differentiation of colonic regulatory T cells and also 
induce the expression of N-acetylglucosamine 6-O-sulfotransferase-2 that modifies 
mucin-type O-glycans in the gut3, 4). Moreover, the presence of certain bacterial 
metabolites has frequently been associated with the incidence of behavioral abnormalities 
of the host5). It is therefore not exaggerated to consider the intestinal bacterial population 
as an organ of the host. Hence, it is important to understand what shapes and influences 
this consortium of intestinal bacteria. 
Dietary habits have been assumed to significantly affect the gut microbial 
composition. This concept is true in most part, because gut microbiomes are shown to 
vary among communities with different diets6) and also to change rapidly within 
individuals when their diets change7). Non-digestible glycans in diets are thus the main 
factor affecting the gut microbial community. The genomes of several gut microbes 
contain genetic loci responsible for the utilization of plant-derived glycans, such as pectic 
polysaccharides and xyloglucans, and the foraging activity of these bacteria allows them 
to thrive in the gut ecosystem8). Our group reported the isolation of the genes encoding 
1,2-α-L-fucosidase and endo-α-N-acetylgalactosaminidase from bifidobacteria in 2004 
and 2005, respectively9, 10). Both enzymes act on host-derived glycans, including milk 
oligosaccharides and mucin glycoproteins, and interestingly, the homologues of these 
enzymes were found to be conserved in particular gut microbes11). Based on these findings, 
we envisaged that the host-derived glycans are also an important and influential factor for 
the microbial composition in the gut11) (Note that a host genetic factor, e.g. secretor or 
non-secretor, has been recently shown to affect gut microbiota composition12)). 
The composition of human gut microbiota changes during life, and the most drastic 
adaptations occur at the start of breast-feeding and the end of it, i.e., during weaning13, 14). 
The intestines of breast-fed infants are rapidly and dominantly colonized by 
bifidobacteria within a week after birth, and the bifidobacteria-rich population drastically 
decreases after weaning15, 16). This observation strongly suggests that human milk 
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contains compounds (perhaps, host-derived glycans) that selectively stimulate the growth 
of bifidobacteria in the infant gut. The presence of bifidobacteria in the gut microbiota 
appears to be correlated with a reduced incidence of diseases such as diarrhea and 
allergies in infants17). Various beneficial effects of bifidobacteria on host health have been 
reported, including the inhibition of harmful bacteria17), fortification of barrier function 
of intestinal epithelial cells18), and modulation of immune function19). Thus, the bacteria 
might be the first evolutionary commensals in the human gut, but the molecular 
mechanism underlying the formation of bifidobacteria-rich microbiota in the intestines of 
breast-fed infants remains elusive. In this review, I summarize the advances made by our 
group over the past 10 years on bifidobacterial enzymes that are dedicated to the 
degradation of human milk oligosaccharides (HMOs; see section III for definition), in the 
context of the historical research efforts on bifidobacteria and HMOs. The structure-
function analysis of the bifidobacterial enzymes indicates a symbiosis and co-evolution 
between bifidobacteria and humans. 
 
II. Historical background 
Bifidobacterium sp. (first named Bacillus bifidus communis) was isolated in 1899 
from the feces of breast-fed infants by H. Tissier at the Pasteur Institute. He already 
mentioned at the time that the gut microbiota of breast-fed infants are richer in 
bifidobacteria as compared to the feces of bottle-fed infants20). Although the ratio of 
occupancy varies in different studies and with different detection techniques (culture 
method vs. non-culture method), it is currently well established that an increased 
population of bifidobacteria and a decreased population of other, especially pathogenic, 
bacteria, are specific features of the intestinal microflora of breast-fed babies13-15). The 
finding that bifidobacteria are predominantly present in the gut of breast-fed newborns 
and that the bacteria showed enhanced growth on media supplemented with human, but 
not cow, milk20, 21), convinced researchers that human milk contains bifidogenic 
compounds (or bifidus factors). 
In 1954, Gauhe et al. reported that the oligosaccharides in human milk have a 
bifidogenic effect22). They partially purified the relevant oligosaccharides and found they 
consisted of L-fucose (Fuc), galactose (Gal), glucose (Glc), and N-acetylglucosamine 
(GlcNAc). The concept that HMOs acted as bifidus factors was attractive. However, the 
interpretation of these experiments was later disputed, because they used a variant strain 
of Bifidobacterium sp. (Bifidobacterium bifidum var. pennsylvanicus) that was probably 
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impaired in its ability to synthesize GlcNAc-containing cell-wall components22, 23). It 
should be mentioned, however, that most bifidobacteria do not utilize exogenously added 
GlcNAc efficiently24). Therefore, the above observation should not be attributed to misuse 
of the variant strain only. Indeed, Gauhe et al. mentioned in their paper that many 
bifidobacterial strains isolated from the breast-fed infants showed the same phenotype as 
Bifidobacterium bifidum var. pennsylvanicus21). Since then and up to 2004, there were no 
reports indicating a biological connection between HMOs and bifidobacteria. In the last 
two decades, many researchers focused instead on the anti-microbial and 
immunomodulatory activities of HMOs. Ruiz-Palacios et al. showed that HMOs with an 
H-antigen structure (Fucα1-2Gal) inhibit Campylobacter jejuni infection in an in vivo 
mouse model25), and Crane et al. found that HMOs block the binding of enterotoxins of 
Escherichia coli to intestinal cells26). Reduction of the binding of human 
immunodeficiency virus-1 to dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin was also reported27). In addition, disialyllacto-N-tetraose was 
shown to ameliorate necrotizing enterocolitis in rats28). These studies, combined with a 
continuous advance of analytical instruments, have become the driving force to decipher 
various biological functions of HMOs. 
 
III. Human milk oligosaccharides (HMOs) 
Oligosaccharides (with a degree of polymerization of more than 3) are the third 
most abundant solid component in human milk (between 10 and 20 g/L), after lactose 
(Lac) and lipids, and they are collectively termed HMOs29). HMOs are characterized by 
their complex structures, and more than 200 molecular species have been detected30). 
They are divided into 13 core structures that consist of Lac at the reducing end, elongated 
by β1-3-linked lacto-N-biose I (Galβ1-3GlcNAc: LNB, type-1 chain) and/or β1-3/6-
linked N-acetyllactosamine (Galβ1-4GlcNAc: LacNAc, type-2 chain). The core 
structures are frequently modified by Fuc and sialic acid (Neu5Ac) via α1-2/3/4 and α2-
3/6 linkages, respectively, to more complex structures31). Among these HMOs, lacto-N-
tetraose (LNT, Galβ1-3GlcNAcβ1-3Galβ1-4Glc), lacto-N-fucopentaose I (LNFP I, 
Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glc), lacto-N-difucohexaose I (LNDFH I, Fucα1-
2Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc), and 2′-fucosyllactose (2′-FL, Fucα1-
2Galβ1-4Glc) are the most abundant, especially in the colostrum, unless the milk is 
derived from non-secretor and/or Lewis-negative subjects (Fig. 1)29, 31). It should be noted 
that HMOs are especially rich in type-1 chains, as is the case for three of the above 
structures (LNT, LNFP I, and LNDFH I), as this composition is unique for human milk 
oligosaccharides29). The type-1 richness of HMOs constitutes one of the rationales behind 
6 
 
the concept of symbiosis and co-evolution between bifidobacteria and humans, details of 
which are described in sections IV and V.  
Considering the mother’s energy expenditure to synthesize 10−20 g/L of HMOs in 
the mammary glands (one ATP is theoretically consumed per elongation of one sugar 
residue), they should represent a relevant biological advantage to infants32). One 
important activity of HMOs is, as mentioned above, to defend neonates from infectious 
disease. HMOs are resistant to the host’s intestinal digestive enzymes33), and thus the 
majority should reach the colon, where they exert their activity. Another activity of HMOs 
is the modulation of immune responses17, 19). A small amount of HMOs is detected in the 
urine and plasma of infants, sometimes modified by acetylation and further 
glycosylation34, 35). He et al. showed that 2′-FL can attenuate the lipopolysaccharide-
induced inflammatory response of intestinal epithelial cells in vitro36). As discussed in 
this review, one of the most important activities of HMOs is to enhance the development 
of a bifidobacteria-rich microbial population, by acting as their preferred nutrient. Infant-
gut associated bifidobacteria possess the specific genetic and enzymatic toolsets 
dedicated to the assimilation of HMOs. 
 
IV. Specific occurrence of HMO-degrading enzymes in infant gut-associated 
bifidobacteria 
Bifidobacterium breve, B. bifidum, B. longum subsp. infantis (referred to as B. 
infantis), and B. longum subsp. longum (B. longum) are four well-known 
species/subspecies found in the stool of breast-fed babies15, 37). In 1999, Derensy-Dron et 
al. reported the presence of a phosphorylase specific for galacto-N-biose (GNB, Galβ1-
3GalNAc) and lacto-N-biose I (LNB, Galβ1-3GlcNAc) in B. bifidum38). The enzyme 
catalyzes the phosphorolysis of GNB and LNB to produce α-D-galactose 1-phosphate and 
the respective N-acetylhexosamines. Subsequently, Kitaoka et al. isolated the 
corresponding gene from B. longum and fully characterized the enzyme39). GNB is the 
disaccharide liberated from core-1 type O-glycan (Galβ1-3GalNAcα-O-Ser/Thr) by 
endo-α-N-acetylgalactosaminidase (isolated from B. longum) (see Section I) 10). Given 
that GNB/LNB phosphorylase (GLNBP) is located in the cytoplasm while endo-α-N-
acetylgalactosaminidase is cell-wall-anchored with its catalytic domain exposed to the 
outer surface, the liberated GNB needs being imported by a specific transporter. Not 
surprisingly, the genes encoding an unidentified ATP-binding cassette (ABC)-type sugar 
transporter were found upstream of the GLNBP gene. The presence of GLNBP 
(intracellular) and endo-α-N-acetylgalactosaminidase (extracellular) in bifidobacteria 
also suggested that these organisms possess an extracellular enzyme that liberates LNB 
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from host-derived glycans. LNB (type-1 chain) is present as a constituent of glycan chains 
of various glycoconjugates, including glycosphingolipids, mucin glycoproteins, and 
importantly HMOs (Fig. 1. see section III)31). Kitaoka et al. thus proposed that LNB is a 
bifidus factor39). Accordingly, the molecular cloning of 1,2-α-L-fucosidase, endo-α-N-
acetylgalactosaminidase, and GLNBP became an important clue to elucidate the disputed 
role of HMOs as bifidus factors. In the following sections, I shortly describe the key 
enzymes required to degrade the three main components of type-1 HMOs (LNT, LNFP I, 
and LNDFH I) (Fig. 1). 
 
Lacto-N-biosidase (LNBase) 
Twenty eight bacterial species/subspecies belonging to the Bacteroides, 
Bifidobacterium, Clostridium, Enterococcus, Eubacterium, Lactobacillus, and 
Ruminococcus genera, which constitute main human gut microbiome, were examined for 
their ability to liberate LNB from LNT40). Of these 28 (sub)species, all strains of B. 
bifidum and two strains of B. longum tested positive (LNBase+). The gene for LNBase 
was isolated from B. bifidum based on the sequence of the Streptomyces sp. LNBase, 
which was the sole enzyme identified at that time41). The gene, designated lnbB, was 
found to encode a protein of 1,112 amino acid residues with a predicted molecular mass 
of 120 kDa. The deduced amino acid sequence contained a signal peptide and a membrane 
anchor at the N-terminal (1–34 aa) and C-terminal (1082–1108 aa) ends. The database 
search revealed the presence of an N-terminal glycoside hydrolase family 20 (GH20) 
domain (179–496 aa)42), a central carbohydrate-binding module 32 (CBM32; 784–932 
aa), and a C-terminal bacterial immunoglobulin (Ig)-like 2 domain (960–1041 aa)40) (Fig. 
2A). The LnbB protein exhibited 38% amino acid identity to the LNBase from 
Streptomyces sp. and 20 to 25% identity to β-N-acetylhexosaminidases (β-HexNAc-ases) 
from bacterial and mammalian sources43, 44). Hydrolysis by GH20 enzymes is known to 
proceed through a substrate-assisted mechanism, in which the N-acetyl group of the 
substrate (in the case of LNT, this is GlcNAc) attacks its own anomeric carbon to form 
an oxazoline intermediate44). The important catalytic residues identified in β-Hex-ases 
were conserved in LnbB40). Interestingly, while LNBase acts on β-linked LNB and to a 
lesser extent on β-linked GNB, it does not act on β-linked HexNAc monosaccharides. In 
contrast, β-HexNAc-ases act on β-linked HexNAc, but not on β-linked LNB/GNB 
disaccharides, even though the linkage to be hydrolyzed is the same and both enzymes 
belong to the same GH family40, 43-45). To understand the molecular basis of the substrate 
recognition by each enzyme and to subsequently be able to distinguish between the two 
at the sequence level, our group solved the crystal structure of the catalytic domain of 
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LnbB (41–663 aa) in complex with LNB at 1.8-Å resolution (Fig. 2B)46). The structures 
of complexes with competitive inhibitors with Ki values of 0.1–50 µM have recently also 
been determined47). As shown in the molecular surface models of the two enzymes (B. 
bifidum LnbB and human β-HexNAc-ase)45), LNBase possesses an extended pocket (-2 
subsite) suitable for accommodating the β-(1→3)-linked Gal residue of LNB (Fig. 2C), 
and forms several hydrogen bonds with Gal46). In contrast to LNBase, Hsβ-HexNAc-ase 
possesses a catalytic pocket that can accept one HexNAc residue and the corresponding 
site (Gal-binding site of LNBase) is occupied by the residues extending from the β1 and 
β2 sheets and the following loop region, which become a steric hindrance for the 
accommodation of LNB. LNBase lacks a residue that recognizes the O3 atom of -1 
GlcNAc, which could prevent it from forming a stable transition-state intermediate in the 
absence of the -2 Gal residue, leading to the loss of HexNAc-ase activity. As this 
information provided us with a rationale for how the two enzymes differently recognize 
their respective substrates, we were able to discriminate between the two enzymes at the 
amino acid sequence level. The homologues of LnbB (i.e. LNBase, not β-HexNAc-ase) 
are found in the genomes of B. bifidum (all of the sequenced strains), Trueperella 
pyogenes (an isolate from bovine mastitis), Actinomyces neuii (an isolate from mammary 
prosthesis), Chlamydia trachomatis, and some species of Streptomyces, which indicates 
the specific presence of LNBase in bifidobacteria. The structural studies also suggested 
that LNBase evolved from β-HexNAc-ase. 
The genome sequence of B. longum JCM1217 became publicly available in 201148). 
Although the strain was shown to be phenotypically LNBase+, no homologous gene to 
lnbB of B. bifidum was found. The gene product containing the GH20 domain was 
identified to be β-GlcNAc-ase49). Expression cloning was carried out to isolate the 
LNBase gene from the strain, and consequently, locus_tag BLLJ_1505 and BLLJ_1506 
were identified50). BLLJ_1505 (termed LnbX) showed no sequence similarity to the 
previously characterized proteins but was found to possess a signal peptide (1–30 aa), a 
right-handed β-helix region (158–315 aa), an uncharacterized sugar-binding domain 
called FIVAR (1435–1487 aa), and a membrane anchor (1577–1593 aa). BLLJ_1506 
(termed LnbY) has a signal peptide (1–29 aa) as well, but lacks any functional motifs. 
Enzymatic and genetic characterization revealed that LNBase from B. longum is 
comprised of the gene product of lnbX only, while the gene product of lnbY acts as a 
designated chaperon for LnbX. The purified LnbX contained Ca2+ and Mg2+ ions, and 
denatured LnbX efficiently refolded when both LnbY and the two metal ions were present. 
LnbY did not contain any metal ion. The lnbX and lnbY genes constitute an operon, as the 
polar effect was observed when the lnbX gene was disrupted in B. longum50). The substrate 
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specificity of LnbX was also found to be unique. Although GH20 LnbB is active on the 
unmodified LNB structure (e.g. LNT), LnbX was able to hydrolyze LNFP I and 
sialyllacto-N-tetraose a (LST a) to release 2′-fucosyl LNB and 3′-sialyl LNB, respectively. 
However, the activities are considerably lower than that for LNT, and therefore not 
physiologically relevant (Table 1. See section V). Moreover, LnbX was found to act on 
the β-linked GNB present in sugar chains of globosides (Gb5 and globo H), but it was 
inactive on GA1 tetrasaccharide in which β-GNB is linked with the axial O4 of the Gal 
residue. GH20 LnbB was capable of acting on GA1 and Gb5 oligosaccharides but not on 
globo H hexasaccharide51). LnbX homologues are found in the genomes of gut microbes 
belonging to Bifidobacterium, Roseburia, Eubacterium, Ruminococcus, and Clostridium, 
whereas LnbY homologues are found only in B. longum and B. bifidum (note that LnbY 
homologues of B. bifidum lack a signal sequence)52). Considering the unique maturation 
process of LnbX and LnbY, it should be empirically determined whether these 
homologues have LNBase activity. Structural studies of LnbX and LnbY are currently 
ongoing, which will help us understand the unique features of these two enzymes. 
 
Galacto-N-biose/lacto-N-biose I transporter (GNB/LNB transporter) 
As mentioned above, the genes for an ABC transporter were found to be located 
just upstream of the GNB/LNB phosphorylase (GLNBP) gene in the B. longum genome39). 
When they were introduced into B. longum strain 105-A on a plasmid, the resulting strain 
was found to show a 10-fold increase in the uptake of (14C-labelled) LNB as compared 
with the control strain carrying an empty plasmid (unpublished results). This indicates 
the direct involvement of the genes in LNB transport. The substrate specificity of the 
ABC transporter is primarily defined by the solute-binding protein, and therefore we 
purified and characterized the corresponding protein of the transporter53). The purified 
protein (termed GL-BP) was shown by isothermal calorimeter analysis to specifically 
bind GNB and LNB with a Kd value of 10 and 87 nM, respectively. The protein had a low 
affinity for LNT (Kd of 11 µM), but it was completely heat silent towards 
monosaccharides constituting the disaccharides (i.e. Gal, GlcNAc, and GalNAc), and 
disaccharides Lac and LacNAc (type-2 chain). The binding was enthalpy-driven with a 
slight negative entropy change. Subsequent X-ray structural analysis revealed that the 
binding was primarily dependent on hydrogen bonds. Interestingly, the axial O4 of the 
GalNAc residue of GNB forms a water-mediated hydrogen bond with the GL-BP protein, 
which is absent in the LNB-complex. This might correspond to the difference in enthalpy 
change in the binding of the two ligands (8 kcal/mol)53). It should be noted that the 
genomic locus of this transporter in B. longum lacks a gene encoding an ATP-binding 
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protein, required to provide energy for the transport. However, it is not rare for gram-
positive bacteria to use one ATP-binding protein to energize several ABC transporters54). 
Homologues of the LNB/GNB transporter were found in the genomes of several 
bifidobacteria (B. longum, B. bifidum, B. breve, B. infantis, B. pseudocatenulatum, B. 
animalis, and B. pseudolongum), as well as in the genomes of skin-, and vagina-
colonizing bacteria such as Propionibacterium acnes and Mobiluncus curtisii, 
respectively. Thus, the distribution of the LNB/GNB transporter in gut microbes is 
exclusively limited to bifidobacteria, and to the best of our knowledge, all strains 
belonging to infant gut-associated bifidobacteria (B. longum, B. bifidum, B. breve, B. 
infantis) possess the gene cluster. GNB/LNB phosphorylase (GLNBP), isolated by 
Kitaoka et al., is also exclusively found in the genomes of bifidobacteria39). 
 
Lacto-N-tetraose β-1,3-galactosidase (LNT-Gal-ase) 
In 2008, Sela et al. determined the genomic sequence of B. infantis55). They found 
that this subspecies has a gene cluster dedicated to the degradation of HMOs (termed 
HMO cluster-1) on its genome and hypothesized that the presence of this cluster is linked 
to the ability of the respective strains to grow on HMOs. Interestingly, none of the 
glycosidases encoded in the cluster were found to possess a signal sequence. Therefore, 
Sela et al. predicted that the organism imports intact HMOs into the cytoplasm prior to 
degradation55). Indeed, when B. infantis cells were incubated with LNT, the 
tetrasaccharide disappeared from the culture supernatant, and during the incubation 
period, no mono-, di-, and trisaccharides appeared in the spent medium56). The uptake 
involves an ABC transporter, as the activity was completely abolished in the presence of 
an ABC transporter inhibitor. Degradation of LNT by B. infantis inside the cells involves 
monosaccharide-releasing exo-glycosidases because liberation of Gal, GlcNAc, and Glc 
was observed when LNT was incubated with the cell-free extract. This was an intriguing 
finding because the β-galactosidase (β-Gal-ase) located in the HMO cluster-1 was 
considered to be specific for type-2 chains as it belongs to GH242). Taking these findings 
into consideration, the genome of this subspecies was scrutinized, and 6 candidate genes 
were isolated and the recombinant proteins were characterized enzymatically. From these 
6 candidates, the protein with locus_tag Blon_2016 (belonging to GH42), not located at 
the locus HMO cluster-1, was found to efficiently liberate Gal from LNT (kcat/Km of 120 
mM-1 s-1) (Table 1), while the other enzymes, including GH2 β-Gal-ase from the HMO 
cluster-1, were inactive on LNT56). This was the second report at the time describing the 
isolation of a β-Gal-ase that hydrolyzes type-1 chains, and the first report to show that the 
GH42 enzyme degrades human-derived glycans. GH42 members had been assumed to 
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degrade plant-derived glycans42). Interestingly, LNT-Gal-ase was shown to have a higher 
affinity for LNT than for LNB, even though the scissile bond is the same in the two 
substrates. Probably, the enzyme has a (+) subsite that interacts with the Lac moiety of 
LNT. Our results also revealed that the HMO degradation capacity of B. infantis could 
not be exclusively attributed to HMO cluster-156). 
Recent reports by Viborg et al. have shown that the substrate specificity of different 
GH42 enzymes is more diverse than previously anticipated based on their phylogenetic 
distances (Fig. 3A)57, 58). For example, the amino acid sequence of Gal-ase (locus_tag 
Balac_0484, termed BlGal42A) from B. animalis subsp. lactis is 62% identical to that of 
LNT-Gal-ase of B. infantis. Nonetheless, it hardly acts on LNT (Fig. 3B) but shows a 
preference for galactooligosaccharides with β-(1→6/3) linkages 57). On the other hand, B. 
bifidum β-Gal-ase, which is 74% identical to B. infantis LNT-Gal-ase, was found to be 
capable of hydrolyzing LNT although its efficiency is less than that of the B. infantis 
enzyme (Fig. 3B). Structural studies are necessary to understand the molecular basis of 
the differential substrate recognition by these similar enzymes at the (+) subsites. From 
bacteria to humans, only four enzymes (all GH35 and GH42 members) have been 
reported so far to act on type-1 chains, suggesting that this type of activity is quite rare in 
nature42). Homologues (> 74% identity) of LNT-Gal-ase of B. infantis were found 
exclusively in infant gut-associated bifidobacteria (B. longum, B. bifidum, B. breve, and 
B. infantis) (Fig. 3A). 
 
Our group also enzymatically and structurally characterized 1,2-α-L-fucosidase9, 59, 
60) and 1,3-1,4-α-L-fucosidase61, 62) of bifidobacteria. Both enzymes are indispensable for 
the removal of Fuc residues from HMOs, prior to the action of the three type-1 specific 
enzymes mentioned above. Lack of α-L-fucosidase activity is known to severely impair 
the ability of bifidobacteria to utilize HMOs, because about 70% of all HMOs are 
fucosylated (except for non-secretors)29). GH95 or 1,2-α-L-fucosidase is present in B. 
bifidum (secretory form), B. infantis (cytosolic from), some strains of B. breve (cytosolic 
from), and a few gut bacteria belonging to Bacteroides, Clostridium and Ruminococcus, 
but it has not been identified in B. longum. The other fucosidase, 1,3-1,4-α-L-fucosidase 
(GH29 subfamily B) removes Fuc residues from Lewis a/x trisaccharide structures 
(Galβ1-3/4(Fucα1-4/3)GlcNAcβ) but not from Fucα1-4/3GlcNAc disaccharides, and it is 
found in B. bifidum (secretory form), B. infantis (cytosolic form), and Bacteroides 
thetaiotaomicron, but not in B. breve and B. longum. The unique feature of 1,3-1,4-α-L-
fucosidase that requires a branched Gal residues has been identified by x-ray structural 
studies62, 63). Lactobacillus casei has a cytoplasmic α-L-fucosidase specific for Fucα1-
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3GlcNAc disaccharides64). However, it remains to be elucidated whether this enzyme is 
involved in HMO degradation because action of this enzyme on HMO structures requires 
prior removal of Gal residues. 
Taken together, these findings suggest that infant gut-associated bifidobacteria have 
evolved specific enzymes dedicated to the degradation of type-1 HMOs. The metabolic 
process of LNB inside the cells has been summarized by Kitaoka65). The limited 
occurrence of the homologues of HMO-degrading enzymes in bifidobacteria has also 
been reported by Odamaki et al.66). 
 
V. Consumption of HMOs by infant gut-associated bifidobacteria 
The ability of certain species of bifidobacteria to assimilate HMOs was first 
demonstrated by Ward et al. and LoCascio et al. in 200767, 68), and not much later also by 
Marcobal et al.69). By analyzing the oligosaccharides present in the spent media by mass 
spectrometry, these authors found that B. infantis can consume a range of HMO structures, 
whereas B. breve and B. longum exhibit only a very limited utilization of HMOs. The 
authors also showed that some Bacteroides sp. degrade HMOs. 
Our group first examined LNT (type-1 chain) degradation by various gut microbes 
and found that this activity is limited to infant-gut-associated bifidobacteria (data not 
shown). No degradation of LNT, or even liberation of Gal, was detected in the cell 
suspensions of other intestinal bacteria belonging to Bacteroides, Clostridium, 
Lactobacillus, Enterococcus, and Eubacterium. Only in the supernatant of B. 
thetaiotaomicron cultures, a small amount of the trisaccharide lacto-N-triose II 
(GlcNAcβ1-3Galβ1-4Glc) was identified. Given these results, we examined the in vitro 
fermentation ability of infant gut-associated bifidobacteria and precisely determined the 
metabolic fate of each of the neutral HMOs during cultivation, by using HPLC to detect 
2-anthranilic-acid-labelled sugars24). The merits of HPLC detection of fluorescein-
labelled sugars over mass spectrometry are (1) highly sensitive quantification of sugars 
(mono- and oligosaccharides), and (2) reliable isomer separation (type-1 versus type-2). 
When the selected strains of infant gut-associated bifidobacteria were incubated in 
medium containing HMOs as the carbon source, B. bifidum JCM1254 and B. infantis 
JCM1222 showed vigorous growth (OD600 > 1.5). The growth of B. breve JCM1192 and 
B. longum JCM1217 was significantly lower, as the OD600 value never exceeded 0.4. 
HPLC analysis of the mono- and oligosaccharides in the spent media revealed that B. 
breve JCM1192 and B. longum JCM1217 consumed LNT only (Fig. 4). B. longum used 
lacto-N-biosidase (LnbX) to degrade LNT, as a transient increase in Lac accompanied the 
decrease in LNT. A slight decrease in LNFP I was observed, which reflects the substrate 
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specificity of LnbX, but this decrease seemed not physiologically relevant. LNB was not 
detected during this period, suggesting that B. longum prefers LNB over Lac. In contrast, 
B. breve appeared to consume LNT without hydrolyzing it outside the cells. In other 
words, B. breve directly imported the tetrasaccharide, because no mono- or di-saccharide 
degradation products were detected. In accordance, neither LNT-Gal-ase nor LNBase 
activity was detected in the extracellular fraction of B. breve JCM11192. The genomes of 
the 7 strains of this species do not possess homologues for the secretory β-galactosidase 
or for LNBase52). 
As expected, B. infantis imported a wide variety of intact HMOs (Fig. 4). All 
oligosaccharides disappeared when the organism entered the logarithmic phase, which 
was followed by a temporal increase in a small amount of monosaccharides (Fuc, Gal, 
and Glc). The transient increase of monosaccharides might be a counteraction against the 
osmotic pressure caused by the rapid uptake of large amounts of HMOs. The HMO 
consumption behavior of B. infantis is consistent with the metabolic ability deduced by 
the genomic analysis55). B. infantis encodes 20 genes of family 1 solute-binding proteins 
of the ABC transporter, seven of which are located in the HMO cluster-1. Based on a 
glycan array analysis, Garrido et al. showed that some of the isolated solute-binding 
proteins indeed recognize the glycan structures found in HMOs, although further 
biochemical studies are needed to clarify which transporter is exactly involved in the 
uptake of each of the HMOs70). B. infantis is equipped with all types of glycosidases 
required to hydrolyze the linkages of HMOs in its cytoplasm, and thus consumed all 
HMOs from the medium55, 56, 62). B. bifidum, another avid HMO consumer, was found to 
degrade HMOs in a different manner. As 1,2-α-L-fucosidase, 1,3-1,4-α-L-fucosidase, and 
LNBase of B. bifidum are secretory enzymes9, 62), the organism degraded HMOs into 
mono- and disaccharides extracellularly. Unexpectedly, this degradation occurred before 
the species entered the exponential growth phase (Fig. 4). The degraded mono- (Fuc, Gal, 
and Glc) and disaccharides (LNB and Lac) were abundantly present in the culture medium 
of B. bifidum between the early and mid-logarithmic phases24). Even after degrading all 
kinds of HMOs and entering the stationary phase, monosaccharides remained 
unconsumed. Similar to B. longum, B. bifidum also has a preference for LNB over Lac. 
Nonetheless, the LNB concentration (1.3 mM) at the lag phase (before entering 
logarithmic phase) reached to half of the sum of the initial concentrations of LNT and 
LNFP I. The Lac concentration became equal to the sum of LNT and LNFP I. These 
results suggest that these metabolites are shared among gut microbes, especially among 
bifidobacteria24). Importantly, the GNB/LNB transporter, GNB/LNB phosphorylase 
(GLNBP), and LNB assimilation ability are limited to infant-gut-associated 
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bifidobacteria71, 72). B. infantis appears to be ‘selfish’ in utilizing HMOs, while B. bifidum 
is ‘altruistic’. It is interesting to note that Tannock et al. found that the population and 
diversity of bifidobacteria increase significantly when B. bifidum occupies > 10% of the 
total bifidobacterial counts in infant feces, as compared with the case that B. bifidum 
population counts for less than 10%37). They also mentioned that this phenomenon only 
occurs in breast-fed babies, strongly suggesting the symbiotic sharing of HMOs among 
bifidobacteria. 
B. infantis and B. bifidum were able to consume type-2 HMOs efficiently24, 73). The 
hydrolysis of type-2 oligosaccharides occurs respectively inside and outside of B. infantis 
and B. bifidum cells. Our group has already identified β-galactosidase that specifically 
acts on lacto-N-neotetraose (Galβ1-4GlcNAcβ1-3Galβ1-4Glc)56) and β-HexNAc-ase that 
is highly specific for lacto-N-triose II (GlcNAcβ1-3Galβ1-4Glc)73). 
 
VI. Concluding remarks 
The gut microbial population of breast-fed infants constitutes a tripartite 
relationship between the mother’s milk, the infant, and bacteria. In general, bifidobacteria 
constitute a larger part of the microbiota of breast-fed newborns than of that of bottle-fed 
babies13-15). Albrecht et al. examined the profiles of the oligosaccharides present in the 
milk of breast-feeding mothers and the feces of the corresponding infants and found that 
the HMO degradation in the infant’s digestive tract is highly variable74). In one case, an 
oligosaccharide lacking the LNB moiety of fucosyllacto-N-hexaose II was identified in 
the infant feces (and was not present in the mother’s sample), which strongly suggests the 
action of LNBases in the intestine of the infant. In the same sample, a reduction in 
fucosylated oligosaccharides and LNT was observed. Although the oligosaccharide 
profile in milk did not change significantly during the first six months after giving a birth, 
the profiles of infant feces showed drastic changes. This indicates that the changes in 
oligosaccharide degradation in the infant digestive tract are linked with a maturation 
process of gut microbiota74). De Leoz et al. have recently confirmed that infants with 
bifidobacteria-rich gut-microbiota exhibit a more extensive HMO degradation in their 
feces than infants with microbiota with less bifidobacteria, although this study only 
compared the feces of two babies75). In combination with the above mentioned our 
findings, it is therefore highly likely that HMOs serve to stimulate the growth of 
bifidobacteria to dominate the infant gut microbial population. 
In retrospect, the 1954 report by Gauhe et al. describing oligosaccharides consisting 
of Fuc, Gal, Glc, and GlcNAc that act as bifidus factor was fairly accurate22). Although 
their results were dismissed based on the use of a variant (perhaps, mutant) strain of 
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bifidobacteria, they already mentioned that bifidobacterial strains with the same 
phenotype (i.e. requiring HMOs for rapid growth, but not cow milk) were frequently 
isolated from the stool of breast-fed babies. Unfortunately, these pioneering findings 
could not be validated at the time because of a lack of genetic and analytical tools. In 
addition, it was difficult to conceive that the specific assimilation of HMOs by 
bifidobacteria involves and relies on the uptake of di- or longer saccharides (LNB, LNT, 
LNFP I etc.).  
HMOs have no apparent nutritional value for infants, even though they are the third 
most abundant component in human milk. Nevertheless, human females have evolved to 
produce a large amount of HMOs (10–20 g/L) in the mammary glands at a great expense 
of energy29). Apart from the structural diversity among mammals, milk oligosaccharides 
also appeared in monotreme species (platypus and echidna)76). Urashima et al. have 
claimed that the original function of milk oligosaccharides is the prevention of microbial 
infection (HMOs also work in that way), and that the roles of milk oligosaccharides have 
diversified later during evolution76). In a rare case of cross-kingdom symbiosis, humans 
and bifidobacteria might have succeeded in mutually exploiting HMOs as beneficial 
compounds, as deduced by the fact that the presence of type-1 chain-specific enzymes is 
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Figure 1. The structure of four main HMOs, and the enzymes involved in the degradation 
of the HMOs in infant gut-associated bifidobacteria. B. infantis and B. bifidum consume 
a variety of HMOs but the assimilation pathways are very different. B. breve and B. 
longum utilize LNT only. LNB produced and left unconsumed by B. bifidum may be 
shared among the other bifidobacteria expressing both the GNB/LNB transporter and 
GNB/PNB phosphorylase. This figure was made by modifying Supplementary Figure S1 
of our original paper24). 
 
Figure 2. Structural differences between B. bifidum GH20 lacto-N-biosidase (LnbB) and 
human GH20 N-acetylhexosaminidase (HexA). (A) Domain organization of LnbB (left) 
and HexA (right). (B) Overall structures of LnbB (catalytic domain; PDB ID: 4H04) 
(cyan) and HexA (PDB ID: 2GK1) (pink) shown in a ribbon model. The catalytic core of 
both enzymes consists of a (β/α)8 barrel fold. (C) The active site structures of LnbB and 
HexA shown in a surface model. LNB and GlcNAc-thiazoline are depicted by a stick 
model.  
 
Figure 3. Different substrate specificities of the GH42 members. (A) A phylogenetic tree 
was constructed with the GH42 enzymes from bifidobacteria77). (B) Thin-layer 
chromatography analysis shows that Bga42A (LNT-Gal-ase) from B. infantis and BbgII 
from B. bifidum (74% identical) degrade LNT, while Gal42A (62% identical) from B. 
animalis subsp. lactis and Bga42B/C (45% and 27% identical) from B. infantis do not 
(Gal42A can hydrolyze the substrate to a limited extent). The members that show LNT-
Gal-ase activity (Bga42A and BbgII) and their closest homologues (> 95% identity) are 
enclosed by a dashed oval. The GenBank ID and (sub)species names (ad, B. adolescentis; 
bi, B. bifidum; br, B. breve; de, B. dentium; in, B. infantis; la, B. animalis subsp. lactis; lo, 
B. longum; and ps. B. pseudocatenulatum) are indicated.  
 
Figure 4. Metabolic fates of the four main HMO components (green: 2'-FL; purple: LNT; 
cyan: LNFP I; and orange: LNDFH I) during cultivation with infant gut-associated 
bifidobacteria. The concentrations of LNB (blue) and Lac (brown) are also shown. See 
also Figure 1. The sugars in the spent media were analyzed by HPLC: (A) B. infantis 
JCM1222, (B) B. bifidum JCM1254, (C) B. longum JCM1217, and (D) B. breve JCM1217. 
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TABLE 1. Substrate specificities of type-1 chain-specific glycosidases from infant gut-associated bifidobacteria 
 
a The reaction products were analyzed by thin-layer chromatography.  
b The kinetic parameters are taken from our papers 40, 50, 56).  
























Galβ1-3GlcNAcβ1-3Galβ1-4Glc + + + 0.63 67 0.40 282 2.2 120           
Lacto-N-neotetraose 
Galβ1-4GlcNAcβ1-3Galβ1-4Glc - − +     na 1.1           
Lacto-N-hexaose 
Galβ1-3GlcNAcβ1-3(Galβ1-4GlcNAcβ1-6)Galβ1-4Glc + + + nd nd nd nd nd nd           
Lacto-N-fucopentaose I 
Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glc − + −   15 0.92             
Lacto-N-fucopentaose II 
Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc - − −                 
Sialyllacto-N-tetraose a 
Neu5Acα2-3Galβ1-3GlcNAcβ1-3Galβ1-4Glc − + −   nd     nd   
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